Balanced Pharma Inc
OperatingBiotech · Cornelius, NC
Financials
FY2020–FY2022 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inDotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.
Cap table
Share counts as of Dec 31, 2022| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Common stock | 20,762,398 | — | 100.0% | $4.00Mar 2022 |
Shares outstanding over timein today's share terms
Principal holders% as the filing states it, May 1, 2023
- J. Scott Keadle9,682,000 Common Stock42.0%of company
- Everyone else (not named in filings)58.0%
Sold to the crowd
- Reg A+ · Mar 2022271,760 Common Stock at $4.00$1.1M
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
4 peopleNames and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.
SEC filings
View all 16 filings on EDGAR- Form D/ASep 23, 20250001838860-25-000007EDGAR
- Form DJan 15, 20250001838860-25-000001EDGAR
- Form DDec 12, 20240001838860-24-000002EDGAR
- Form DDec 12, 20240001838860-24-000003EDGAR
- Form 1-ZSep 6, 20230001104659-23-098411EDGAR
- Form 1-KMay 1, 20230001104659-23-053330EDGAR
- Form 253G2Mar 30, 20230001104659-23-039255EDGAR
- Form 1-SASep 16, 20220001104659-22-100549EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.